Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology

Overview

Journal Diabetes Ther

Specialty Cardiology & Vascular Diseases

Date 2014 Nov 27

PMID 25424969

Citations 138

Authors

Sanjay Kalra

Affiliations

Soon will be listed here.

Abstract

Sodium-glucose co-transporter-2 (SGLT2) inhibitors are a newly developed class of oral anti-diabetic drugs (OADs) with a unique mechanism of action. This review describes the biochemistry and physiology underlying the use of SGLT2 inhibitors, and their clinical pharmacology, including mechanism of action and posology. The pragmatic placement of these molecules in the existing OAD arena is also discussed.

Citing Articles

Challenges, current innovations, and opportunities for managing type 2 diabetes in frail older adults: a position paper of the European Geriatric Medicine Society (EuGMS)-Special Interest Group in Diabetes.

Boccardi V, Bahat G, Balci C, Bourdel-Marchasson I, Christiaens A, Donini L Eur Geriatr Med. 2025; .

PMID: 40014274 DOI: 10.1007/s41999-025-01168-1.

Fixed dose combination of dapagliflozin, glimepiride and extended-release metformin tablets in patients with type 2 diabetes poorly controlled by metformin and glimepiride: A phase III, open label, randomized clinical study in India.

Sahay R, Gangwani D, Singh M, Gupta S, Kale N, Srivastava M Diabetes Obes Metab. 2025; 27(4):2193-2205.

PMID: 39950245 PMC: 11885079. DOI: 10.1111/dom.16218.

SGLT2 Inhibitor Use in Chronic Kidney Disease: Supporting Cardiovascular, Kidney, and Metabolic Health.

Madero M, Chertow G, Mark P Kidney Med. 2025; 6(8):100851.

PMID: 39822934 PMC: 11738012. DOI: 10.1016/j.xkme.2024.100851.

Cutaneous Adverse Drug Reactions Associated with SGLT2 Inhibitors.

Mederle A, Dumitrescu P, Borza C, Kundnani N J Clin Med. 2025; 14(1.

PMID: 39797270 PMC: 11721703. DOI: 10.3390/jcm14010188.

Hemodynamic Effects of SGLT2 Inhibitors in Patients with and Without Diabetes Mellitus-A Narrative Review.

Brata R, Pascalau A, Fratila O, Paul I, Muresan M, Camarasan A Healthcare (Basel). 2024; 12(23).

PMID: 39685086 PMC: 11641081. DOI: 10.3390/healthcare12232464.

References

Ehrenkranz J, Lewis N, Kahn C, Roth J . Phlorizin: a review. Diabetes Metab Res Rev. 2004; 21(1):31-8. DOI: 10.1002/dmrr.532. View

Cherney D, Perkins B . Sodium-glucose cotransporter 2 inhibition in type 1 diabetes: simultaneous glucose lowering and renal protection?. Can J Diabetes. 2014; 38(5):356-63. DOI: 10.1016/j.jcjd.2014.05.006. View

Ptaszynska A, Johnsson K, Parikh S, de Bruin T, Apanovitch A, List J . Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events. Drug Saf. 2014; 37(10):815-29. DOI: 10.1007/s40264-014-0213-4. View

Bolinder J, Ljunggren O, Johansson L, Wilding J, Langkilde A, Sjostrom C . Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2013; 16(2):159-69. DOI: 10.1111/dom.12189. View

Lavalle-Gonzalez F, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W . Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013; 56(12):2582-92. PMC: 3825495. DOI: 10.1007/s00125-013-3039-1. View

Sarnoski-Brocavich S, Hilas O . Canagliflozin (invokana), a novel oral agent for type-2 diabetes. P T. 2014; 38(11):656-66. PMC: 3875253. View

Lee Y, Han H . Regulatory mechanisms of Na(+)/glucose cotransporters in renal proximal tubule cells. Kidney Int Suppl. 2007; (106):S27-35. DOI: 10.1038/sj.ki.5002383. View

Nagata T, Fukazawa M, Honda K, Yata T, Kawai M, Yamane M . Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats. Am J Physiol Endocrinol Metab. 2012; 304(4):E414-23. DOI: 10.1152/ajpendo.00545.2012. View

Nauck M, Del Prato S, Duran-Garcia S, Rohwedder K, Langkilde A, Sugg J . Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes Obes Metab. 2014; 16(11):1111-20. DOI: 10.1111/dom.12327. View

10.

Fujita Y, Inagaki N . Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action. J Diabetes Investig. 2014; 5(3):265-75. PMC: 4020327. DOI: 10.1111/jdi.12214. View

11.

Ohtake Y, Sato T, Kobayashi T, Nishimoto M, Taka N, Takano K . Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem. 2012; 55(17):7828-40. DOI: 10.1021/jm300884k. View

12.

Stenlof K, Cefalu W, Kim K, Jodar E, Alba M, Edwards R . Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Curr Med Res Opin. 2013; 30(2):163-75. DOI: 10.1185/03007995.2013.850066. View

13.

Cherney D, Perkins B, Soleymanlou N, Maione M, Lai V, Lee A . Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2013; 129(5):587-97. DOI: 10.1161/CIRCULATIONAHA.113.005081. View

14.

Wilding J, Woo V, Soler N, Pahor A, Sugg J, Rohwedder K . Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012; 156(6):405-15. DOI: 10.7326/0003-4819-156-6-201203200-00003. View

15.

Hummel C, Lu C, Loo D, Hirayama B, Voss A, Wright E . Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2. Am J Physiol Cell Physiol. 2010; 300(1):C14-21. PMC: 3023189. DOI: 10.1152/ajpcell.00388.2010. View

16.

Wright E . Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol. 2001; 280(1):F10-8. DOI: 10.1152/ajprenal.2001.280.1.F10. View

17.

Kalra S, Baruah M, Sahay R . Medication counselling with sodium glucose transporter 2 inhibitor therapy. Indian J Endocrinol Metab. 2014; 18(5):597-9. PMC: 4171879. DOI: 10.4103/2230-8210.139206. View

18.

Kasichayanula S, Liu X, LaCreta F, Griffen S, Boulton D . Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2013; 53(1):17-27. DOI: 10.1007/s40262-013-0104-3. View

19.

Bailey C . Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci. 2011; 32(2):63-71. DOI: 10.1016/j.tips.2010.11.011. View

20.

Ruggenenti P, Porrini E, Gaspari F, Motterlini N, Cannata A, Carrara F . Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care. 2012; 35(10):2061-8. PMC: 3447826. DOI: 10.2337/dc11-2189. View